title: Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease.
abstract: Modifications occurring on autoantigens during cell death have been proposed to have a role in the initiation of autoimmune diseases. Patients suffering from mixed connective tissue disease (MCTD) produce autoantibodies directed to U1 small nuclear ribonucleoprotein (snRNP), and antibodies against a 70 kDa protein component, the U1-70K (70K) protein, are the most prominent. During apoptosis, 70K is cleaved by caspase-3 to a 40 kDa product, which remains associated with the complex. Autoantibodies preferentially recognizing the apoptotic form of 70K have been described previously, and an apoptosis-specific epitope on 70K has been identified. This study shows that 29 of 53 (54%) MCTD sera preferentially recognize the apoptotic form of 70K over intact 70K. Moreover, we show that antibodies directed to an apoptosis-specific epitope on 70K are more specifically associated with MCTD than other anti-70K antibodies, suggesting that apoptotic 70K is a better antigen for the detection of these antibodies in MCTD patients. Longitudinal analysis of 12 MCTD patients showed in several patients that early sera are relatively enriched with antibodies recognizing an apoptosis-specific epitope, and that the levels of these apoptosis-specific antibodies decrease in time. These findings indicate that the early detection of apoptotic 70K is of considerable interest for anti-U1 snRNP-positive patients.
authors.affiliation: Department of Biochemistry, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands. d.hof@ncmls.kun.nl
authors.forename: Daniëlle
authors.initials: D
authors.lastname: Hof
authors.forename: Kalok
authors.initials: K
authors.lastname: Cheung
authors.forename: Dirk-Jan R A M
authors.initials: DJ
authors.lastname: de Rooij
authors.forename: Frank H
authors.initials: FH
authors.lastname: van den Hoogen
authors.forename: Ger J M
authors.initials: GJ
authors.lastname: Pruijn
authors.forename: Walther J
authors.initials: WJ
authors.lastname: van Venrooij
authors.forename: Jos M H
authors.initials: JM
authors.lastname: Raats
mesh_terms: D000841:Anisomycin / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000097:blood* / Q000175:diagnosis; D015415:Biomarkers; D015153:Blotting, Western; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D015331:Cohort Studies; D018450:Disease Progression; D042241:Early Diagnosis; D000939:Epitopes / Q000276:immunology; D006801:Humans; D019169:Jurkat Cells / Q000187:drug effects; D008947:Mixed Connective Tissue Disease / Q000097:blood* / Q000175:diagnosis; D017434:Protein Structure, Tertiary; D017412:Ribonucleoprotein, U1 Small Nuclear / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D015415:Biomarkers; D000939:Epitopes; D017412:Ribonucleoprotein, U1 Small Nuclear; C490688:SNRNP70 protein, human; D000841:Anisomycin; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases
references.citation: Arthritis Rheum. 1998 Jul;41(7):1152-60
references.pmid: 9663470
references.citation: Arthritis Rheum. 1998 May;41(5):768-77
references.pmid: 9588728
references.citation: Scand J Rheumatol. 2001;30(5):282-9
references.pmid: 11727843
references.citation: J Biol Chem. 1994 Dec 9;269(49):30757-60
references.pmid: 7983001
references.citation: Arthritis Rheum. 2003 Oct;48(10):2741-9
references.pmid: 14558078
references.citation: J Immunol. 2004 Jan 1;172(1):709-16
references.pmid: 14688384
references.citation: Clin Exp Rheumatol. 1997 Sep-Oct;15(5):549-60
references.pmid: 9307865
references.citation: Biochim Biophys Acta. 1990 Nov 30;1087(3):265-92
references.pmid: 2147394
references.citation: Clin Immunol Immunopathol. 1990 Feb;54(2):266-80
references.pmid: 2104788
references.citation: Rev Rhum Engl Ed. 1998 Jun;65(6):378-86
references.pmid: 9670329
references.citation: Cell Death Differ. 2000 Jan;7(1):70-9
references.pmid: 10713722
references.citation: Arthritis Rheum. 2002 May;46(5):1264-9
references.pmid: 12115232
references.citation: Eur J Immunol. 2000 Oct;30(10):3029-38
references.pmid: 11069087
references.citation: J Immunol. 1982 Mar;128(3):1176-80
references.pmid: 6173424
references.citation: Arthritis Rheum. 1997 Apr;40(4):672-82
references.pmid: 9125249
references.citation: Arthritis Res. 2000;2(2):101-14
references.pmid: 11094420
references.citation: Proc Natl Acad Sci U S A. 1979 Nov;76(11):5495-9
references.pmid: 316537
references.citation: Isr Med Assoc J. 2002 Sep;4(9):706-12
references.pmid: 12440236
references.citation: Arthritis Rheum. 1992 Oct;35(10):1202-10
references.pmid: 1384511
references.citation: Arthritis Rheum. 2004 Feb;50(2):380-6
references.pmid: 14872479
references.citation: Cell. 1994 Jun 17;77(6):805-15
references.pmid: 7516265
references.citation: Cell Death Differ. 1999 Jan;6(1):6-12
references.pmid: 10200542
references.citation: Arthritis Rheum. 2001 Nov;44(11):2642-52
references.pmid: 11710720
references.citation: Am J Med. 1972 Feb;52(2):148-59
references.pmid: 4621694
references.citation: Arthritis Rheum. 2001 Feb;44(2):368-75
references.pmid: 11229468
references.citation: J Exp Med. 1999 Sep 20;190(6):815-26
references.pmid: 10499920
references.citation: Arthritis Rheum. 2000 Apr;43(4):881-8
references.pmid: 10765934
references.citation: Arthritis Rheum. 1990 May;33(5):634-43
references.pmid: 2346519
references.citation: J Exp Med. 1996 May 1;183(5):1957-64
references.pmid: 8642305
references.citation: Curr Opin Immunol. 1995 Dec;7(6):819-24
references.pmid: 8679126
references.citation: J Immunol. 2002 Sep 15;169(6):3429-37
references.pmid: 12218166